TISIDB

Summary
Symbol	CDC25C
Name	cell division cycle 25C
Aliases	PPP1R60; protein phosphatase 1, regulatory subunit 60; cell division cycle 25 homolog C (S. cerevisiae); cel ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF06617 M-phase inducer phosphatase PF00581 Rhodanese-like domain
Function	Functions as a dosage-dependent inducer in mitotic control. Tyrosine protein phosphatase required for progression of the cell cycle. When phosphorylated, highly effective in activating G2 cells into prophase. Directly dephosphorylates CDK1 and activates its kinase activity.

> Gene Ontology [ TOP ]
Biological Process	GO:0000075 cell cycle checkpoint GO:0000077 DNA damage checkpoint GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000082 G1/S transition of mitotic cell cycle GO:0000086 G2/M transition of mitotic cell cycle GO:0006260 DNA replication GO:0006470 protein dephosphorylation GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0007050 cell cycle arrest GO:0007067 mitotic nuclear division GO:0007088 regulation of mitotic nuclear division GO:0007093 mitotic cell cycle checkpoint GO:0007283 spermatogenesis GO:0007346 regulation of mitotic cell cycle GO:0010948 negative regulation of cell cycle process GO:0016311 dephosphorylation GO:0030330 DNA damage response, signal transduction by p53 class mediator GO:0031570 DNA integrity checkpoint GO:0031571 mitotic G1 DNA damage checkpoint GO:0035335 peptidyl-tyrosine dephosphorylation GO:0042770 signal transduction in response to DNA damage GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044773 mitotic DNA damage checkpoint GO:0044774 mitotic DNA integrity checkpoint GO:0044783 G1 DNA damage checkpoint GO:0044819 mitotic G1/S transition checkpoint GO:0044839 cell cycle G2/M phase transition GO:0044843 cell cycle G1/S phase transition GO:0045786 negative regulation of cell cycle GO:0045787 positive regulation of cell cycle GO:0045930 negative regulation of mitotic cell cycle GO:0048232 male gamete generation GO:0051783 regulation of nuclear division GO:0071156 regulation of cell cycle arrest GO:0071158 positive regulation of cell cycle arrest GO:0071900 regulation of protein serine/threonine kinase activity GO:0072331 signal transduction by p53 class mediator GO:0072395 signal transduction involved in cell cycle checkpoint GO:0072401 signal transduction involved in DNA integrity checkpoint GO:0072413 signal transduction involved in mitotic cell cycle checkpoint GO:0072422 signal transduction involved in DNA damage checkpoint GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint GO:0090068 positive regulation of cell cycle process GO:1901987 regulation of cell cycle phase transition GO:1901988 negative regulation of cell cycle phase transition GO:1901990 regulation of mitotic cell cycle phase transition GO:1901991 negative regulation of mitotic cell cycle phase transition GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint GO:1902402 signal transduction involved in mitotic DNA damage checkpoint GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint GO:1902806 regulation of cell cycle G1/S phase transition GO:1902807 negative regulation of cell cycle G1/S phase transition GO:1904029 regulation of cyclin-dependent protein kinase activity GO:2000045 regulation of G1/S transition of mitotic cell cycle GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
Molecular Function	GO:0004721 phosphoprotein phosphatase activity GO:0004725 protein tyrosine phosphatase activity GO:0016791 phosphatase activity GO:0042578 phosphoric ester hydrolase activity GO:0050699 WW domain binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04110 Cell cycle hsa04114 Oocyte meiosis hsa04914 Progesterone-mediated oocyte maturation
Reactome	R-HSA-176187: Activation of ATR in response to replication stress R-HSA-1640170: Cell Cycle R-HSA-69620: Cell Cycle Checkpoints R-HSA-69278: Cell Cycle, Mitotic R-HSA-75035: Chk1/Chk2(Cds1) mediated inactivation of Cyclin B R-HSA-69273: Cyclin A/B1 associated events during G2/M transition R-HSA-157881: Cyclin B2 mediated events R-HSA-8862803: Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models R-HSA-1643685: Disease R-HSA-69481: G2/M Checkpoints R-HSA-69473: G2/M DNA damage checkpoint R-HSA-69275: G2/M Transition R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-453274: Mitotic G2-G2/M phases R-HSA-8863678: Neurodegenerative Diseases R-HSA-156711: Polo-like kinase mediated events R-HSA-195258: RHO GTPase Effectors R-HSA-5625740: RHO GTPases activate PKNs R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes R-HSA-6804114: TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest R-HSA-6804115: TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain R-HSA-3700989: Transcriptional Regulation by TP53

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04110 Cell cycle
hsa04114 Oocyte meiosis
hsa04914 Progesterone-mediated oocyte maturation

Reactome

R-HSA-176187: Activation of ATR in response to replication stress
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-75035: Chk1/Chk2(Cds1) mediated inactivation of Cyclin B
R-HSA-69273: Cyclin A/B1 associated events during G2/M transition
R-HSA-157881: Cyclin B2 mediated events
R-HSA-8862803: Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
R-HSA-1643685: Disease
R-HSA-69481: G2/M Checkpoints
R-HSA-69473: G2/M DNA damage checkpoint
R-HSA-69275: G2/M Transition
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-8863678: Neurodegenerative Diseases
R-HSA-156711: Polo-like kinase mediated events
R-HSA-195258: RHO GTPase Effectors
R-HSA-5625740: RHO GTPases activate PKNs
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804114: TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
R-HSA-6804115: TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
R-HSA-3700989: Transcriptional Regulation by TP53

Summary
Symbol	CDC25C
Name	cell division cycle 25C
Aliases	PPP1R60; protein phosphatase 1, regulatory subunit 60; cell division cycle 25 homolog C (S. cerevisiae); cel ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CDC25C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CDC25C
Name	cell division cycle 25C
Aliases	PPP1R60; protein phosphatase 1, regulatory subunit 60; cell division cycle 25 homolog C (S. cerevisiae); cel ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CDC25C in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CDC25C
Name	cell division cycle 25C
Aliases	PPP1R60; protein phosphatase 1, regulatory subunit 60; cell division cycle 25 homolog C (S. cerevisiae); cel ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CDC25C in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.376	0.138
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.467	0.502
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.316	0.613
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.167	0.755
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.505	0.62
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.267	0.839
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.018	0.956
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.423	0.581
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.526	0.477
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.594	0.4
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.684	0.473
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.591	1.89e-05

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CDC25C in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	2.7	8.4	0.12
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	3.4	7.7	0.176
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CDC25C
Name	cell division cycle 25C
Aliases	PPP1R60; protein phosphatase 1, regulatory subunit 60; cell division cycle 25 homolog C (S. cerevisiae); cel ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDC25C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CDC25C
Name	cell division cycle 25C
Aliases	PPP1R60; protein phosphatase 1, regulatory subunit 60; cell division cycle 25 homolog C (S. cerevisiae); cel ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDC25C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDC25C. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CDC25C
Name	cell division cycle 25C
Aliases	PPP1R60; protein phosphatase 1, regulatory subunit 60; cell division cycle 25 homolog C (S. cerevisiae); cel ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDC25C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CDC25C
Name	cell division cycle 25C
Aliases	PPP1R60; protein phosphatase 1, regulatory subunit 60; cell division cycle 25 homolog C (S. cerevisiae); cel ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CDC25C expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CDC25C
Name	cell division cycle 25C
Aliases	PPP1R60; protein phosphatase 1, regulatory subunit 60; cell division cycle 25 homolog C (S. cerevisiae); cel ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CDC25C and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CDC25C
Name	cell division cycle 25C
Aliases	PPP1R60; protein phosphatase 1, regulatory subunit 60; cell division cycle 25 homolog C (S. cerevisiae); cel ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CDC25C collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CDC25C